Allied Market Research has published a study report with the title Gene Therapy Market Size was Valued at USD 6.0 billion in 2020 and is Projected to Garner USD 46.5 billion by 2030, registering a CAGR of 22.8% from 2021 to 2030. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.
๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐๐๐๐ญ๐จ๐ซ๐ฌ ๐๐ซ๐ข๐ฏ๐ข๐ง๐ ๐ญ๐ก๐ ๐๐๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐๐ซ๐ค๐๐ญ?
Increase in the prevalence of chronic disorders, rise in government support, and ethical acceptance of gene therapy for cancer treatment drive the growth of the global gene therapy market. On the other hand, high cost of gene therapies restrains the growth to some extent. However, the presence of advanced healthcare infrastructure is anticipated to pave the way for lucrative opportunities in the industry.
๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐ซ๐๐ฉ๐ก๐ฌ ๐๐ง๐ ๐ ๐ข๐ ๐ฎ๐ซ๐๐ฌ ๐๐๐ซ๐: https://www.alliedmarketresearch.com/request-sample/2841
๐๐จ๐ฉ ๐๐๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ:
- Gilead Sciences
- Orchard Therapeutics.
- Bristol-Myers Squibb.
- Therapeutics plc
- Adverum Biotechnologies, Inc.
- Amgen Inc.
- Jazz Pharmaceuticals,
- Shenzhen SiBiono Genentech
- Adaptimmune
- Novartis AG
- Shanghai Sunway Biotech Co., Ltd.
๐๐๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง ๐๐๐ง ๐๐ ๐๐จ๐ง๐ ๐๐๐ฌ๐๐ ๐จ๐ง ๐ฌ๐๐ฏ๐๐ซ๐๐ฅ ๐๐๐๐ญ๐จ๐ซ๐ฌ, ๐ข๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ :
On the basis of gene type, the antigen segment accounted for the highest market share in 2020, generating nearly one-fourth of the global gene therapy market. Rise in the prevalence of diseases such as autoimmune diseases & cancer and increase in R&D activities associated with antigen-based gene therapies propel the growth of the segment. The deficiency segment, however, is anticipated to cite the fastest CAGR of 26.0% from 2021 to 2030.
On the basis of application, the oncological disorders segment generated the highest share in 2020, holding more than two-fifths of the global gene therapy market. The same segment is also expected to cite the fastest CAGR of 23.5% from 2021 to 2030. Increase in the prevalence of cancer and availability of diverse gene therapy products that can be used to treat cancer fuel the segment growth.
On the basis of region, North America contributed to the major market share in terms of revenue 2020, holding nearly half of the global gene therapy market. The Asia-Pacific region, simultaneously, is projected to cite the fastest CAGR of 25.4% from 2021 to 2030. This is attributed to the facts such as rise in the prevalence of chronic diseases, increase in healthcare expenditure, developments in healthcare infrastructure, availability of reimbursements, and the presence of major market players in the province.
Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/2841
By Region Outlook
- North America
(U.S., Canada, Mexico)
- Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
- LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Contact Details:
David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
